America’s LNP Supply Chain Race Is Redefining RNA Drugs

US demand for lipid nanoparticles is reshaping RNA drug timelines as delivery partnerships and manufacturing access become decisive

16 Jan 2026

The effort to scale RNA medicines in the US is entering a more industrial phase, as manufacturing capacity and delivery partnerships begin to shape how quickly new therapies can reach patients.

Lipid nanoparticles, or LNPs, which protect and transport RNA into cells, sit at the centre of this shift. Their use was validated at scale during the Covid-19 vaccine rollout, and demand has since broadened as RNA-based therapies move into oncology, rare diseases and chronic conditions. Industry forecasts point to strong growth in the US LNP market through the next decade, driven by wider adoption across vaccines and advanced drug delivery platforms.

The industry’s focus is now less on whether LNPs work and more on whether they can be produced reliably and at commercial scale. Developers are increasingly concerned about access to specialised lipids, formulation expertise and quality-controlled manufacturing processes.

As a result, partnership activity has taken on greater importance. Drugmakers are using agreements with contract development and manufacturing organisations, or CDMOs, to secure capacity early and reduce supply chain risk. Evonik, which has a long history in lipid-based drug delivery, has highlighted its LNP and liposome manufacturing capabilities as demand from RNA developers increases.

Delivery technology is also influencing intellectual property strategies. Genevant Sciences, which holds a broad portfolio of patents covering lipid nanoparticle delivery and next-generation nucleic acid platforms, has positioned its technology as a key component of long-term development plans for RNA drugmakers.

Across the sector, delivery is becoming a source of differentiation rather than a secondary consideration. Analysts and investors increasingly assess companies not only on the promise of their science, but on their ability to manufacture stable products at scale. This has implications for procurement, quality systems and commercial planning.

Constraints remain. LNP supply chains are specialised, capacity expansion can lag demand, and changes to manufacturing processes often require additional testing that can extend development timelines. Even so, activity across the market continues to build.

As RNA pipelines expand, the US LNP ecosystem is evolving toward a model in which manufacturing readiness and delivery partnerships play a larger role in competitive positioning. For developers, the ability to scale delivery systems with consistency and confidence is becoming a central part of the path to market.